Last updated: February 13, 2026
What is the current market status of the drug with NDC 68462-0228?
NDC 68462-0228 corresponds to Kybella (deoxycholic acid), manufactured by Allergan (now part of AbbVie). Approved by the FDA in 2015 for submental fat reduction, Kybella has established itself in the aesthetics market as a non-surgical alternative to liposuction.
How is Kybella positioned in the competitive landscape?
Kybella faces competition from both surgical and non-surgical submental fat reduction therapies:
- Surgical options: Liposuction, neck lifts.
- Non-surgical options: CoolSculpting (ZF Medical/Allergan), SculpSure (Cynosure).
In 2022, Kybella's global sales approached $250 million, marking it as a key player but not dominant in the fat reduction segment.
What are the primary factors influencing Kybella’s market share?
- Efficacy and safety profile: FDA approval and minimal downtime enhance appeal.
- Brand recognition: Allergan's established reputation benefits sales.
- Reimbursement policies: Coverage varies, impacting patient affordability.
- Physician adoption: Steady increase in procedures, but growth is plateauing.
What are current pricing trends for Kybella?
Pricing per treatment session varies by geography and provider, generally ranging from $600 to $1,200. On average, patients undergo 2-4 treatments, accruing a total cost of $1,200 to $4,800.
In the U.S., the average cost for a full treatment regimen is approximately $2,500, with some providers offering discounts for multiple sessions or package deals.
How do pricing trends compare with competitors?
| Product |
Average Cost per Treatment |
Total Treatments Needed |
Estimated Total Cost |
| Kybella |
$600 - $1,200 |
2-4 |
$1,200 - $4,800 |
| CoolSculpting |
$750 - $1,500 per cycle |
1-3 cycles |
$750 - $4,500 |
| Liposuction |
$2,000 - $4,000 per procedure |
1 |
$2,000 - $4,000 |
What are projections for Kybella's market over the next five years?
Based on current market trends, Kybella is expected to experience moderate growth, driven by:
- An aging population seeking minimally invasive procedures.
- Increasing acceptance of non-surgical fat reduction.
- Expansion into new markets and indications.
Market research predicts a Compound Annual Growth Rate (CAGR) of approximately 6% from 2023 to 2028. By 2028, global sales could approach $350-$400 million, assuming steady market penetration and no regulatory or reimbursement shifts.
What are the key risks and opportunities?
Risks:
- Market saturation in the U.S. and mature markets.
- Competition from newer modalities and technologies.
- Reimbursement restrictions limiting patient access.
- Regulatory hurdles in emerging markets.
Opportunities:
- Expanding indications (e.g., other fat deposits).
- Increasing adoption in mid-tier clinics.
- Strategic partnerships for distribution expansion.
- Uptake in international markets with growing aesthetic procedures.
What are the price projection assumptions?
The projections assume:
- Stable reimbursement policies.
- Continued physician acceptance.
- No significant price discounting pressures.
- Incremental market expansion into new geographies and indications.
Prices per treatment are expected to remain within recent ranges, with slight inflation adjustments. Overall, total market value is projected to grow steadily, influenced mainly by volume increases rather than price escalation.
Closing Summary
Kybella remains a critical nonsurgical fat reduction product, with market value poised to grow moderately over the next five years. Pricing will likely stay stable within current ranges, supported by demand and brand strength, but growth may slow due to saturation and competitive pressures.
Key Takeaways
- The global Kybella market is estimated to reach $350-$400 million by 2028, with CAGR ~6%.
- Average treatment costs stay around $2,500, with sessions ranging from 2-4.
- Competition from CoolSculpting and liposuction influences market share.
- Market growth is driven by demographic trends and expanding indications.
- Price stability is expected, with volume growth being the primary growth factor.
FAQs
1. How does Kybella’s efficacy compare to other fat reduction treatments?
Kybella effectively dissolves submental fat with minimal downtime. Its efficacy is comparable to CoolSculpting but requires multiple sessions. Liposuction provides immediate results but is invasive.
2. What are reimbursement challenges for Kybella?
Reimbursement varies across insurers and regions. Many insurers do not cover aesthetic procedures, posing out-of-pocket expenses for patients, which can limit market growth.
3. Are there new indications for Kybella?
Research is ongoing into larger or different fat deposits. No major additional indications have received FDA approval yet.
4. What are the geographic market prospects?
North America dominates the market. Europe and Asia-Pacific show growth potential, especially as aesthetic procedures increase in these regions.
5. How does pricing influence competitive positioning?
Affordable treatment packages and flexible financing options influence patient adoption. Price competition can limit premium pricing but also expands accessibility.
Sources:
[1] Allergan’s Kybella product page.
[2] Market research reports by GlobalData and MarketsandMarkets.
[3] U.S. FDA approval data.
[4] Industry sales data, 2022.
